Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Kropff, M; Bisping, G; Schuck, E; Liebisch, P; Lang, N; Hentrich, M; Dechow, T; Kröger, N; Salwender, H; Metzner, B; Sezer, O; Engelhardt, M; Wolf, HH; Einsele, H; Volpert, S; Heinecke, A; Berdel, WE; Kienast, J; Deutsche Studiengruppe Multiples Myelom, 
Titel:
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. 
Abstract:
A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week treatment cycles with bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11, followed by three 5-week cycles with bortezomib 1.3 mg/m(2) on days 1, 8, 15, and 22. Within all cycles, DEX 20 mg/d was given orally...    »
 
Zeitschriftentitel:
Br J Haematol 
Jahr:
2007 
Band / Volume:
138 
Heft / Issue:
Seitenangaben Beitrag:
330-7 
Sprache:
eng 
Print-ISSN:
0007-1048 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik